At Strata Oncology, our goal is to dramatically expand late stage cancer patients’ access to tumor sequencing and precision medicine trials and to accelerate the approval and availability of breakthrough cancer medicines. We are bringing the best minds in oncology together to take on cancer and give the patients that need it most what they deserve – a chance at a better outcome.
One fueled by knowledge and information and one that takes advantage of the latest advances in cancer research. Accelerating innovation, and giving hope to those in need.
Read our press release announcing the launch of Strata Oncology and learn more about our team and partners who have made it possible.
Beginning in early 2017, the Strata Trial will provide no-cost tumor sequencing for 100,000 cancer patients, characterizing the mutations that caused their cancer. In addition, together with our pharma partners, we will offer a portfolio of precision medicine clinical trials that target a wide range of these mutations, with the goal of maximizing the chances that a patient matches to a trial. We plan to bring the Strata Trial to 100+ partner hospitals and cancer centers across the United States, helping to broaden access to tumor sequencing and precision medicine clinical trials. We will continually be looking to add new trials to the portfolio as new precision medicine hypotheses emerge, including biomarker-guided immuno-oncology trials.
Comprehensive Testing. From a small amount of tumor tissue, our test sequences DNA and RNA to accurately report the status of dozens of genetic markers, establishing eligibility for many possible clinical trials.
Portfolio of Treatments. Most clinical trials test just one new medicine. Our platform provides access to a portfolio of possible treatments, each matched to the specific mutations found in a patient’s cancer.
Peace of Mind. After cancer progresses, providers are often left scrambling to find treatment options. By sequencing patients’ tumors before they’ve progressed, we can know in advance which clinical trial a patient is eligible for, should progression occur.
Accelerating precision medicine for cancer patients requires participation from multiple stakeholders. Our belief is that by providing no-cost tumor sequencing to tens of thousands of patients coupled with a portfolio of matching trials, we can be the link - helping healthcare providers find the right clinical trials for their patients and helping pharma companies find the right patients for their trials.
If you represent a pharma company or healthcare provider and are interested in accelerating precision medicine for cancer patients, we invite you to consider joining us. We also invite interested patients, caregivers and advocates to follow our progress.
Together, we can expand opportunities for cancer patients and accelerate the path to new cancer medicines.